This randomized phase 2 study investigated the efficacy of neoadjuvant toripalimab plus celecoxib compared to toripalimab monotherapy in patients with dMMR or MSI-H locally advanced colorectal cancer. The combination therapy significantly increased the pathological complete response rate. The safety profiles were similar between the two groups, supporting further investigation of this combination in larger trials.
Study
|
Randomised, open-label, multicentre, phase 2 trial [PICC-2, NCT03926338] |
| dMMR or MSI-H, locally advanced colorectal cancer |
| Neoadjuvant toripalimab plus celecoxib (n=55) vs toripalimab monotherapy (n=55)
|
Efficacy
|
pCR: 89% vs 69% (celecoxib + toripalimab vs. toripalimab alone)
|
Safety
|
Grade >=3 AE: tumour perforation (4% vs 2%), bowel obstruction (2% vs 0%), rash (0% vs 2%), increased aminotransferase (0% vs 2%), hypothyroidism (0% vs 2%) |
| Serious treatment-related adverse events: 7% vs 7% |
| Treatment-related AE leading to discontinuation: 7% vs 5%
|
Lancet Oncol. Published online July 1, 2026
http://doi.org/10.1016/S1470-2045(26)00220-2
Reviewed by Ulas D. Bayraktar, MD on Aug 13, 2026
